American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 8(67), 2023
DOI: 10.1128/aac.00304-23
Full text: Download
Recent clinical studies have reported additive nephrotoxicity with the combination of vancomycin and piperacillin-tazobactam. However, preclinical models have failed to replicate this finding.